Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. - Wikidata - awgldk - TriplyDB

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

http://www.wikidata.org/entity/Q37613264

about

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options Hepatobiliary quiz-10 (2014)Polyphenol-Rich Fraction of Ecklonia cava Improves Nonalcoholic Fatty Liver Disease in High Fat Diet-Fed Mice.Prevention of nonalcoholic steatohepatitis in rats by two manganese-salen complexes.Hepatobiliary quiz-3 (2012)Role of mitochondria and mitochondria targeted agents in non-alcoholic fatty liver disease.Potential Biological Effects of (-)-Epigallocatechin-3-gallate on the Treatment of Nonalcoholic Fatty Liver Disease.Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models.Metformin and berberine, two versatile drugs in treatment of common metabolic diseases.Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis.

P2860

Q26796448-7868D478-7089-4B83-9A47-37C5BDA306F3 Q34302666-19E916BB-A51C-4FD3-AEED-1E37C4AF2922 Q36329720-7A9D1404-79C3-4387-8791-F9DACD3BBF8D Q37480281-9ED9E043-717D-410E-8A57-FC1082F552AF Q37613918-04170011-E8FF-4D8A-8A3C-91B0FA1CA29D Q46266754-EF9D7C1E-829F-4810-BFF7-5DF44C812158 Q50194612-B34520EC-7A21-4359-95A0-137E47A4F85B Q51304729-A62C278B-9D5A-4987-8DF0-9E53217C0058 Q52668163-155B740E-881E-48BC-BDBE-9D03518A38DA Q54941250-E80B4937-BBCC-45F3-9F20-D0BDC6377D5B

P2860

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

http://www.wikidata.org/entity/Q37613264

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

@en

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

@nl

type

label

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

@en

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

@nl

prefLabel

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

@en

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

@nl

P1433

Q37613264-C7D50568-DD66-4998-B0A6-0DB7EADBFDEE

P1476

Q37613264-768963F0-C250-4FC0-9091-E2829C799CCE

P2093

Q37613264-9BA14B65-DAB2-4FE8-BFB0-A8783E2A57FD

Q37613264-A4B421E6-3A8E-4B95-991E-9427C7FA49E4

P2860

Q37613264-03A0A8D3-F169-4C51-9063-F501C197AA13

Q37613264-044AC060-63DE-4677-A7C9-D381D219E7A7

Q37613264-06CC761C-A02B-4C03-8CF2-065F886760F9

Q37613264-06E3C808-4896-4092-87BE-99AC1C59F30A

Q37613264-07B4443F-7C6B-49C1-8C24-F9FE42859DD9

Q37613264-07F21D2D-0F8A-4A9D-AC91-C7BE907BE9D7

Q37613264-0950D67F-A799-4C08-99DE-AF1982F68C21

Q37613264-0D8D135B-9115-4208-AE8A-2F626D0A9F2A

Q37613264-0DAD1C4B-D825-479A-B1F8-AE1C3DDF5684

Q37613264-10291C18-2BF7-46EF-BC58-AEA28A656C78

P304

Q37613264-576E6507-B79E-4FFC-B23D-D6481C83ED8C

P31

Q37613264-DDF5576C-A5DE-4537-8F45-A0F71B676A91

P356

Q37613264-D61B07BC-EF84-4683-890E-77A1FA6BF9E4

P433

Q37613264-0B9034CE-DF89-4ADA-8ABE-D3A26A063283

P478

Q37613264-0299B62B-767B-4F49-86D1-E62AE00B91AE

P577

Q37613264-932931F0-D437-4D48-B17F-B6F53340E684

P698

Q37613264-7C0F7AFD-EF4C-4723-9E65-B6C446167649

P921

Q37613264-68102F71-7CEB-4633-9841-55CAB32C33A6

P932

Q37613264-DE7324E7-3239-4FDC-8833-6C600F3A0E67

P356

S0973-6883(12)60104-2

P1433

Journal of clinical and experimental hepatology

P1476

Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.

@en

P2093

Rohit Loomba

http://www.w3.org/2001/XMLSchema#string

Thuy-Anh Le

http://www.w3.org/2001/XMLSchema#string

P2860

Role of AMP-activated protein kinase in mechanism of metformin action

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Bariatric surgery for non-alcoholic steatohepatitis in obese patients

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

Cellular and molecular mechanisms of metformin: an overview

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis

P304

156-173

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0973-6883(12)60104-2

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25755424

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

P932

3940181

http://www.w3.org/2001/XMLSchema#string